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Atrial fibrillation (AF) is mostly observed in patients at older age in the presence of 
underlying diseases. However, nowadays clinicians frequently encounter patients with 
AF onset at young age.
objectives.
We studied differences in clinical profile according to age of AF onset.
methods.
We performed a prospective, single-center, observational study. Consecutive patients, 
age < 60 years (‘young AF patients’), with short-lasting AF (<3 years) were compared 
with AF patients with AF onset ≥ 60 years (‘older AF patients’), and with age- and sex-
matched controls (< 60 years). 
Results.
Median age at AF onset was 51 (interquartile range [IQR] 44-54) in young and 66 [IQR 
63-70] years in older patients. Young AF patients were more often men (70% vs. 56%, 
p=0.02), had less hypertension (41% vs. 63%, p<0.001), lower NT-proBNP plasma levels 
in sinus rhythm (83 [IQR 26-119] vs. 159 [IQR 83-298] ng/l, p<0.001), less left ventricular 
hypertrophy or remodeling (20% vs. 40%, p<0.001), better diastolic function, less atrial 
dilatation (39% vs. 55%, p=0.04), and better left atrial reservoir and conduit function. 
Obesity was prevalent both in young (34%) and older (28%) patients. Younger patients 
more frequently had familial AF (28% vs. 12%, p<0.001) and cardiomyopathies (7% vs. 
0%, p=0.007). Lone AF was rare in both groups, 2% vs. 0%, respectively, p=0.25. 
Conclusions.
Distinguishable clinical profiles exist according to age of AF onset. Younger patients 
were more often men with familial AF, who less frequently suffered from hypertension 
and diastolic dysfunction. Even in young patients, lone AF was very rare.
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InTRoduCTIon
Atrial fibrillation (AF) often occurs at advanced age, and most commonly in the presence 
of concomitant cardiovascular disease, such as heart failure, hypertension, coronary 
heart disease and diabetes.(1-4) Yet, clinicians frequently encounter younger patients 
(<60 years) with AF.(4-6)
In epidemiological studies AF incidence in young individuals (aged 20-60 years) 
ranges between 0.17-3.8 per 1000 person years, and AF prevalence from 0.03-1.46%.(4, 
7) However, the incidence of AF in young patients increases.(7) This seems associated 
with changes in life style, consumption pattern and lack of exercise, which may lead to 
earlier development of cardiovascular risk factors and conditions.(7-9) Also risk factors 
for AF may differ between young and older individuals.(10) The relative contribution of 
heritability, as well as contribution of life style-related risk factors such as obesity, and 
lack of or intensive physical exercise may be greater in young individuals.(3) Yet, data on 
the exact clinical phenotype of young onset AF is sparse, since almost all data on clinical 
risk factors for AF are based on older AF patients.(9)
The general notion often is that many young AF patients have lone AF, i.e. AF occur-
ring in the absence of AF risk factors. However recent work suggests that lone AF is 
present only in a minority, and that even in young patients AF often is accompanied with 
significant comorbidities.(11) 
In the present prospective, single-center, observational study we aim to compare the 
clinical risk profile of patients with AF onset <60 years to AF patients aged ≥60 years, as 
well as age- and sex-matched controls. 
meThods
study population.
The Phenotyping Young-Onset Atrial Fibrillation Patients study is a single-center, 
prospective, observational study. The institutional review board approved the study 
protocol. All patients gave written informed consent. Consecutive patients with AF at an 
age <60 years, who were at least 18 years of age and provided written informed consent 
were included. Excluded were patients with post-operative AF, myocardial infarction or 
acute coronary syndrome < 1 month before start of AF, AF due to an acute trigger (e.g. 
sepsis), and patients with hyperthyroidism < 3 month before start of AF. Baseline assess-
ment included a detailed medical history including family history, physical examination, 
12-lead electrocardiogram (ECG), collection of information on underlying disease, con-
ventional and life style-related risk factors for AF, as well as blood samples for biomarker 
analyses. For evaluation of NT-proBNP plasma levels, distinction was made between 
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patients in AF and sinus rhythm at the time of blood collection.(12) Between August 
2012 and December 2013, 500 patients were included in the University Medical Center 
Groningen, The Netherlands. In the present analysis consecutive patients with short-
lasting AF <3 years without prior pulmonary vein isolation (n=120) were compared to 
120 consecutive short lasting (<3 years) AF patients with AF onset ≥60 years who were 
prospectively included in the AF Risk Profile study (clinicaltrials.gov ID: NCT01510210; 
prior pulmonary vein isolation is an exclusion criterion). In addition, comparisons were 
made with age- and sex-matched controls without AF from Prevention of Renal and 
Vascular Endstage Disease study, a community-based study from Groningen, The Neth-
erlands.(7) 
echocardiography.
At baseline patients underwent a standard two-dimensional transthoracic echocardio-
gram (General Electric Vivid E9) during continuous ECG monitoring. Left atrial volume 
was measured using the biplane Simpson’s method. Left ventricular mass and relative 
wall thickness was calculated according to current recommendations to assess left ven-
tricular geometry.(13) In addition, total atrial conduction time (14) and left atrial strain 
measurements were performed.(15) Measurements were indexed for body surface area 
where appropriate. Atrial strain measurements (%) representing atrial reservoir func-
tion and atrial contraction were measured using two-dimensional speckle tracking. A 
lower peak strain value corresponds to less compliant atria walls and an impairment 
of reservoir function.(16) Atrial strain representing conduit function was calculated as 
the difference between strain during atrial reservoir function and atrial contraction. 
Only diastolic function and atrial strain measures collected during sinus rhythm were 
included in the present analysis.
eCg traits suggestive of (subclinical) cardiomyopathies.
ECGs of AF patients during atrial fibrillation and sinus rhythm were adjudicated for traits 
suggestive of (subclinical) cardiomyopathies by two investigators (RAV and ICVG), with 
only access to age, sex and medication use.(17)
definitions.
Hypertension was defined as systolic blood pressure >140mmHg and diastolic blood 
pressure >90mmHg or by use of antihypertensive medication. Diabetes mellitus was 
defined as use of anti-diabetic drugs. Patients were classified as having heart failure 
in the presence of a LVEF≤ 45% (‘reduced ejection fraction’) at baseline or LVEF> 45% 
(‘preserved ejection fraction’) with symptoms associated with heart failure (New York 
Heart Association functional class II or III) or previous hospitalization for heart failure. 
Coronary heart disease was defined as a history of myocardial infarction, percutaneous 
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coronary intervention or coronary artery bypass graft. Peripheral artery disease was 
defined on the basis of a clinical diagnosis by a vascular specialist or observed with dop-
pler ultrasonography or other imaging technique. The ratio of weight to height squared 
(kg/m2) was used for calculation of body mass index (BMI). Obesity was defined as BMI 
>30 kg/m2. High alcohol use was defined as ≥8 units per week. Estimated glomerular 
filtration rate (eGFR) was calculated using the MDRD formula. History of intensive exer-
cise was defined as present or past professional or intensive sports practice. Familial AF 
was defined as a history of AF before age of 60 years in one or more first-degree family 
members. Inflammatory disease includes rheumatoid arthritis, polymyalgia rheumatica, 
inflammatory bowel disease, multiple sclerosis, sarcoidosis (no evidence of cardiac 
involvement), M. Sjögren, psoriasis. Left ventricular (LV) hypertrophy or remodeling was 
classified using left ventricular mass index (LVMI) >95 g/m2(women) or >115 g/m2(men) 
and/or relative wall thickness (RWT) >0.42.(13) Concentric remodeling: LVMI ≤95 g/
m2(women) or ≤115 g/m2(men) and RWT>0.42. Concentric left ventricular hypertrophy: 
LVMI >95 g/m2(women) or >115 g/m2(men) and RWT >0.42. Eccentric left ventricular 
hypertrophy: LVMI >95 g/m2(women) or >115 g/m2(men) and RWT ≤0.42. Diastolic dys-
function was defined as left atrial volume index (LAVI) ≥34 ml/m2 or e’ sept <8 cm/s or e’ 
lat <10 cm/s.(18) Lone AF was defined as absence of any aforementioned risk factors or 
comorbidities, as well as moderate or severe valve disease, cardiomyopathy, prior stroke, 
deep vein thrombosis or pulmonary embolism, high alcohol use, current smoking, BMI 
>25, low voltage ECG, ST elevation in V1-2, ventricular rate <120bpm during AF without 
rate control drugs which is suggestive of intrinsic cardiac disease, and eGFR <60.
statistical analysis.
Descriptive statistics are presented as mean ± standard deviation or median (interquar-
tile range [IQR]) for continuous variables, and numbers with percentages for categorical 
variables. We evaluated differences between young-onset AF patients, older AF patients 
and age- and sex-matched controls at baseline using the chi-square test and Fisher exact 
test for categorical data, and the T-test and Mann-Whitney-U test for continuous data, 
depending on the normality of the data. In secondary analyses, comparisons were made 
between young women and men, and between young women or men with older women 
or men, respectively. When sex-related differences were observed between younger and 
older patients, logistic or linear regression analysis was used to evaluate interactions of 
age (stratified for age <60years and >60years) and sex for these possible differences. If 
appropriate, log transformations were performed to provide normal distribution of re-
siduals in linear regression. In addition we studied the subset of patients who developed 
AF at a very young age (<40 years, n=19). A chi-square test for linear trend was used to 
examine relations of risk factors with the three age groups <40years, 40-60 years and 
>60years. In all analyses a value of p<0.05 was considered statistically significant. 
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ResulTs
differences in clinical risk factors between young and older Af patients.
In young patients, median age of AF onset was 51 (IQR 44-54) years (Table 1). AF tem-
poral patterns were not different between young and older patients. Young patients 
were more often men (70% vs. 56%, p=0.02), had less hypertension, and lower plasma 
NT-proBNP plasma levels (collected in sinus rhythm). Obesity was highly prevalent 
in both young and older patients (34% vs. 28%, p=0.37). Lone AF was rare in both 
groups (2% vs. 0%, p=0.25). Young patients more often performed regular physical 
activity (≥3 times per week) for longer periods of time (>60minutes). Younger pa-
tients more often had familial AF (28% vs. 12%, p<0.001) and cardiomyopathies (7% 
vs. 0%, p=0.007). The Central figure shows the relative importance of AF risk factors 
in both AF groups.
sex related differences in clinical risk factors.
Prevalence of hypertension, coronary heart disease, other traditional risk factors, BMI 
and obesity were comparable between young men (n=84) and young women (n=36). 
However young men more often had high alcohol intake (26% vs. 11%, p=0.03) and 
lower NT-proBNP plasma levels (68 [IQR 24-108] vs. 97 [IQR 69-235] ng/l, p=0.02) than 
young women. supplementary Table 1 shows differences between young and older 
men, and young and older women. Calculation of the interaction between age and sex 
(supplementary Table 2) showed that taller stature in young men compared to older 
men (but not in women), was the only significant sex-related difference in clinical risk 
factors (p=0.01 for interaction between age and sex). 
differences in clinical risk factors between young Af patients and age- and sex-
matched controls.
Compared to age- and sex-matched controls, young AF patients more often had hy-
pertension (41% vs. 21%, p=0.001), higher weight, higher body mass index and were 
more often obese (34% vs. 15%, p<0.001). Young patients also had slower heart rates in 
sinus rhythm and more often had PR-interval >200ms. The prevalence of heart failure, 
myocardial infarction, diabetes mellitus, and stroke was low in young AF patients, and 
comparable to controls. Young AF patients had taller stature than controls, although this 
difference was only found in men when both sexes were analyzed separately (186±8 vs. 
178±6 cm, p<0.001 in men; 172±7 vs. 169±7 cm, p=0.17 in women). No other sex-related 
differences were found between young AF patients and controls.
65Clinical profiles in AF
Table 1. Characteristics of patients with AF onset < 60 years and AF ≥60 years
AF onset <60yr (n=120) AF onset ≥60yr (n=120) P-value
Age AF onset (years) 51 (44-54) 66 (63-70) <0.001
Total AF history (years) 1.5 (0.7-2.4) 0.5 (0.2-1.1) <0.001
Men 84 (70) 67 (56) 0.02
Type of AF 0.08
Paroxysmal 86 (72) 91 (76)
Persistent 29 (24) 29 (24)
Permanent 5 (4) -
AF EHRA class 0.11
I 14 (11) 23 (19)
II 83 (69) 70 (58)
III 21 (18) 27 (23)
IV 2 (2) -
Frequency symptoms 0.22
Occasional (<1x/month) 67 (56) 54 (44)
Intermediate (1x/month to daily) 29 (24) 33 (28)
Frequent (daily) 24 (20) 33 (28)
HFrEF 4 (3) 6 (5) 0.75
HFpEF 1 (1) 4 (3) 0.21
Previous admission for heart failure 4 (3) 7 (6) 0.54
Hypertension 49 (41) 76 (63) <0.001
Diabetes mellitus 9 (8) 18 (15) 0.07
Vascular disease 13(11) 25(21) 0.03
Coronary heart disease 8 (7) 11 (9) 0.47
Peripheral artery disease - 4 (3) 0.12
Prior stroke 5 (4) 11 (9) 0.12
Moderate or severe valve disease 3 (3) 6 (5) 0.50
Cardiomyopathy 8 (7) - 0.007
Hypertrophic 5 (4) - 0.12
Thyroid disease 3 (3) 14 (12) 0.01
Inflammatory disease 4 (3) 9 (8) 0.25
Deep vein thrombosis or pulmonary embolism 3 (3) 4 (3) 1.00
High alcohol use 26 (22) 20 (17) 0.13
Current smoking 19 (16) 16 (13) 0.48
Vagal AF triggers 53 (44) 58 (48) 0.40
Lone AF 2 (2) - 0.25
CHA2DS2-VASc 1 (0-1) 2 (1-3) <0.001
Total number of comorbidities 1 (0-1) 1 (0-1) 0.002
Familial AF 34 (28) 14 (12) <0.001
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Table 1. Characteristics of patients with AF onset < 60 years and AF ≥60 years (continued)
AF onset <60yr (n=120) AF onset ≥60yr (n=120) P-value
Physical examination
Height (cm) 182±10 176±8 <0.001
Weight (kg) 94±17 85±14 <0.001
BMI (kg/m2) 28.4±4.8 27.7±4.5 0.32
Obesity 41 (34) 34 (28) 0.37
Systolic blood pressure (mmHg) 126±19 133±16 0.001
Diastolic blood pressure (mmHg) 80±11 79±9 0.72
Physical activity
Physical activity ≥3 times per week 37 (31) 24 (20) 0.007
Physical activity >60 min per activity 26 (22) 8 (7) <0.001
Moderate/high dynamic 37 (31) 34 (28) 0.20
Moderate/high static 24 (20) 14 (12) 0.02
History of intensive exercise 17 (14) 10 (8) 0.18
Electrocardiogram
Heart rate (bpm, sinus rhythm) 66±11 64±12 0.14
PR interval (ms) 161±26 171±23 0.006
Other ECG abnormalities 13 (11) 6 (5) 0.09
Low voltage ECG 6 (2) 3 (1) 0.50
ST-elevation V1-2 7 (6) 3 (3) 0.33
Echocardiography 
Left atrial parasternal long axis (mm) 39±6 40±6 0.22
Left atrial volume index >34ml/m2 (%) 39 55 0.04
Right atrial length (mm) 53±6 54±7 0.71
Right atrial width (mm) 41±6 40±7 0.51
LV end-diastolic diameter Index (mm/m2) 23 (22-25) 24 (22-25) 0.22
LV end-systolic diameter Index (mm/m2) 15 (13-17) 15 (14-17) 0.18
LV mass index (g/m2) 79 (68-89) 80 (71-92) 0.24
LV hypertrophy or remodeling 24 (20) 48 (40) <0.001
Concentric LV remodeling 18 (15) 35 (29) 0.003
Concentric LV hypertrophy 2 (2) 10 (8) 0.02
Eccentric LV hypertrophy 4(3) 3(3) 1.00
LV ejection fraction (%) 58 (55–60) 58 (55-60) 0.26
E’ septal (cm/s) 10±3 8±2 <0.001
E’ lateral (cm/s) 13±3 9±3 <0.001
E/e’ 6 (5-7) 8 (6-10) <0.001
Diastolic dysfunction (%) 54 88 <0.001
Total atrial conduction time (ms) 130±25 136±25 0.22
LA reservoir function (%) 31±9 26±9 0.003
LA contraction function (%) 12±4 13±5 0.61
LA conduit function (%) 18±7 14±6 <0.001
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Table 1. Characteristics of patients with AF onset < 60 years and AF ≥60 years (continued)
AF onset <60yr (n=120) AF onset ≥60yr (n=120) P-value
Laboratory results
Creatinine (umol/l) 78 (68–86) 78 (71-95) 0.12
eGFR (ml/min*1.73) 87±18 75±17 <0.001
eGFR<60 ml/min 6 (5) 25 (21) <0.001
Total cholesterol (mmol/l) 5.2 (4.6-6.0) 5.0 (4.1-6.0) 0.26
Glucose (mmol/l) 5.5 (5.1-6.0) 6.0 (5.6-6.8) <0.001
NT-proBNP during sinus rhythm (ng/l) 83 (26–119) (n=58) 159 (83-298) (n=59) <0.001
NT-proBNP atrial fibrillation (ng/l) 383 (144–1291) (n=36) 700 (141-1260) (n=43) 0.36
Data is expressed as mean±standard deviation(SD), median(IQR) or numbers(%).
Abbreviations: AF=atrial fibrillation; AF EHRA class=European Heart Rhythm Association AF symptom class; 
BMI=body mass index; bpm=beats per minute; CHA2DS2-VASc=stroke risk index (history of heart failure, hy-
pertension, age >65 or >75 years, diabetes mellitus, stroke or vascular disease); ECG=electrocardiogram; 
eGFR=estimated glomerular filtration rate; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart 
failure with reduced ejection fraction; LA=left atrium; LV=left ventricle; LVMI=left ventricular mass index(g/





































Central Figure. Relative importance of AF risk factors in patients with AF onset <60 years and ≥60 years, based 
on counts of AF risk factors in both age groups. Abbreviations: AF=atrial fibrillation; eGFR=estimated glomerular 
filtration rate.
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echocardiographic differences between young and older patients.
Young onset AF patients less often had LV hypertrophy and LV remodeling (Table 1). 
Young patients also had less often diastolic dysfunction (54% vs. 88%, p<0.001) and en-
larged left atrial volume index >34 ml/m2 (39% vs. 55%, p=0.04), and left atrial reservoir 
and conduit function were better in young vs. older patients (respectively 31±9 vs. 26±9, 
p=0.003 and 18±7 vs. 14±6, p<0.001).
Echocardiographic differences including diastolic function measurements between 
young and older patients were similar in men and women. Although differences in atrial 
and ventricular remodeling seemed most pronounced in women in direct comparisons, 
no significant interactions of age and sex were observed (supplementary Tables 1 and 2).
symptoms according to age of Af onset.
Young patients were more often symptomatic (92% vs. 81%, p=0.02), predominantly 
palpitations (82% vs. 69%, p=0.04). No sex-specific differences in these associations 
were found.
Comparisons with very young Af patients <40 years.
Additional analyses compared very young patients <40 years (n=19) to patients 40-60 
years (n=101) and ≥60 years. Younger age of AF onset was associated with lower preva-
lence of female sex, but higher prevalence of cardiomyopathies (p for trend respectively 
0.03 and <0.001; figure 1A). Higher age of AF onset was associated with hypertension, 
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Figure 1. Prevalence of female sex, familial AF and cardiomyopathy in patients with 
AF onset <40, 40-60 and ≥60 years (A). Prevalence of hypertension in patients with 
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comparable in both younger age groups, but higher than in patients aged ≥60 years 
(respectively 26% vs. 29% vs. 12%, p=0.002). Although numbers were small, relations 
of younger age with less atrial and ventricular remodeling persisted in these analyses.
dIsCussIon
We demonstrate that compared to older patients, young AF patients were more often 
men, being taller, with less often hypertension, lower NT-proBNP plasma levels and 
less signs of left atrial and ventricular remodeling and diastolic dysfunction, but more 
familial clustering of AF and cardiomyopathies. Obesity was highly prevalent in both 
age groups. Compared to age and sex-matched controls, young AF patients more often 
Table 2. Characteristics of patients with AF onset < 60 years, comparison with age- and sex-matched controls 
from PREVEND. 
AF onset <60 yr (n=120) Controls <60 yr (n=120) P-value 
Age (years) 51 (44-54) 51 (44-54) 1.00
Women 36 (30) 36 (30) 1.00
Heart failure 5 (4) - 0.06
Hypertension 49 (41) 25 (21) 0.001
Diabetes mellitus 9 (8) 5 (4) 0.27
Previous myocardial infarction 4 (3) 1 (1) 0.37
Stroke 5 (4) 1 (1) 0.21
Peripheral artery disease - 2 (2) 0.25
Physical examination:
Height (cm) 182±10 176±8 <0.001
Height (cm; women) 172±7 169±7 0.17
Height (cm; men) 186±8 178±6 <0.001
Weight(kg) 94±17 81±12 <0.001
BMI (kg/m2) 28.4±4.8 26.3±3.8 <0.001
Obesity 41 (34) 18 (15) <0.001
Systolic blood pressure (mmHg) 126±19 128±17 0.32
Diastolic blood pressure (mmHg) 80±11 76±9 0.001
Electrocardiogram
Heart rate (in sinus rhythm) 66±11 69±10 0.04
PR interval (ms) 161±26 158±19 0.23
PR interval >200ms 8 (7) 2 (2) 0.047
Data is expressed as mean±standard deviation(SD), median(IQR) or numbers(%).
Abbreviations: AF=atrial fibrillation; BMI=body mass index; NT-proBNP=N-terminal prohormone of brain natri-
uretic peptide.
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had hypertension and obesity, and young AF men were taller. Finally, in both groups the 
prevalence of lone AF was low. 
sex differences.
Young AF patients were more often men. Also, young men with AF were taller than older 
AF men and controls, while no such differences were found in women. The finding that 
young AF patients are more often men than older patients is consistent with data from 
population based studies.(4,19) This difference diminished with increasing age of the 
population. (4,19) Tall stature has also been associated with incident AF before, prob-
ably through anatomically larger atria.(3) Differences in age of onset between sexes may 
possibly relate to different patterns of cardiac gene expression that make men more 
prone to AF at younger age, or alternatively protect young women from AF at younger 
age.(20) A previous study showed that electrophysiological differences exist between 
premenopausal women, post-menopausal women and age-matched men, which may 
protect young women against AF through influence of estrogen.(21) 
hypertension, left ventricular remodeling and diastolic dysfunction.
Hypertension is one of the most prevalent risk factors for AF, both in men and in women.
(3,4,19, 22) Prevalence of hypertension in young AF patients was 41%, which was higher 
than in controls, but lower than in older patients. Hypertension may lead to left ven-
tricular hypertrophy and diastolic dysfunction, both of which have also been identified 
as AF risk factors.(3,23) LV hypertrophy and LV remodeling were present in 20% of young 
patients versus 40% in older patients. Although direct comparisons suggested differen-
tial relations of LV remodeling with age in men and women, no significant interactions 
of sex and age were found.
Young patients also had better diastolic function, lower indexed atrial volumes, better 
atrial function and lower NT-proBNP. The younger age itself and the lower prevalence 
of hypertension in young patients are the most likely contributors to these findings.
(23) Still, atrial function has been reported to be worse than in controls.(24) Diastolic 
dysfunction and atrial remodeling are well known risk factors for AF, though less es-
tablished than other clinical risk factors.(3) Using 2D atrial strain we were able to show 
that older patients had impaired atrial compliance. Impaired atrial function may be one 
of the first markers of atrial remodeling, even occurring before left atrial dilatation.(15) 
obesity and physical exercise.
Obesity was highly prevalent in both young and older AF patients (prevalence ~30%), 
and young patients were more often obese than controls. Obesity often co-exists with 
other cardiovascular risk factors and diseases (e.g. hypertension, diabetes, diastolic 
dysfunction, sleep apnea, sedentary lifestyle), but may also increase AF risk by itself 
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through pro-inflammatory and pro-fibrotic effects of epicardial fat, and even infiltration 
of epicardial fat into the atrial myocardium.(7,8,25,26) Importantly, obesity may be a 
modifiable risk factor. It was recently shown that strict weight reduction diminished AF 
burden, atrial remodeling and left ventricular mass.(27,28) Recently, we showed that 
the population attributable risk of obesity for incident AF was 9%.(7) Theoretically this 
would mean that incidence of AF could be reduced with 9% if the risk factor obesity 
could be completely eliminated.(7) 
Not unexpectedly, young patients more often performed regular physical activity for 
longer durations of time.(29,30) Only a few patients had a history of intensive exercise 
being comparable between both groups. Previous studies showed that both lack of 
and intensive physical exercise may increase AF risk, while moderate physical activity 
protected people from AF (U-shaped curve).(3,29-35) It is thought that increased risk of 
AF in physical inactive individuals may be mediated through obesity-related effects, low 
cardiorespiratory fitness level and other associated risk factors.(7,8,27,36) On the other 
hand, intensive exercise may possibly cause AF through vagal stimuli and/ or increased 
filling pressures during exercise and subsequent atrial remodeling.(3,33-35) In a rat 
model atrial fibrosis was present after 16 weeks of intensive exercise. This fibrosis did not 
regress after cessation of exercise. This suggests that exercise induced fibrosis may be a 
contributor to the occurrence of AF in patients performing intensive exercise.(37) Coun-
seling patients with respect to exercise recommendations seems important since both 
too little and too much exercise may increase risk of AF. Moderate physical exercise may 
protect against AF, through weight loss but also through improving cardiorespiratory 
fitness and reversed structural remodeling.(28,36) Increased awareness of the benefits 
and risks of physical exercise may help prevent AF, and possibly improve cardiovascular 
outcomes.(27,36,38) 
family history of Af and associations with cardiomyopathies in young Af 
patients.
Our results indicate that family history of AF is more common in young-onset AF patients. 
This corresponds to previous data showing that family history of AF was associated with 
increased risk of developing AF, but also with younger age of AF onset.(39,40) Several 
genetic variants or mutations associated with AF may directly lead to AF, or may cause 
AF through cardiovascular risk factors and cardiomyopathies.(41,42) Young AF patients 
also more often had cardiomyopathies. A previous study reported that 17% of families 
with familial AF also presented with dilated cardiomyopathy.(40) In our study, no such 
association could be found. 
Nevertheless our results underline the need for systematic and thorough evaluation 
of young, seemingly ‘lone’ AF patients.(11,43) Remarkably, thorough evaluation of AF 
risk factors in our study lead to a prevalence of lone AF as low as 2%.(11)
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limitations.
In the present cross-sectional analysis we describe differences in clinical risk profile 
between patients with AF occurring at young and older age. Our analyses were limited 
to patients without previous pulmonary vein isolation to provide optimal comparison 
of cardiovascular risk factors and echocardiographic measurements between both age 
groups. Future studies in larger patient populations will involve associations of the 
present phenotypical descriptions with genetic profiles, and associations with cardio-
vascular outcome.
ConClusIons
In the present well characterized cohort young onset AF patients had a high prevalence 
of AF risk factors. Young AF patients were less often women, had less hypertension and a 
less diastolic-dysfunction related risk profile than in older patients. Instead, young onset 
AF was associated with taller height in men and a relatively high prevalence of familial 
AF and cardiomyopathies. Lone AF was very rare. Thus, AF starting at younger age is 
associated with a distinguishable risk profile. This may have implications for therapeutic 
strategies. 
PeRsPeCTIVes
Competency in medical knowledge.
AF is increasingly diagnosed at young age, before the age of 60 years. Even in young 
patients, AF is accompanied with a high prevalence of AF risk factors and comorbidities, 
including obesity. However distinguishable clinical profiles exist according to age of AF 
onset. Younger patients were more often men with familial AF, who less frequently suf-
fered from hypertension and diastolic dysfunction. 
Translational outlook.
More research should be directed toward understanding differences in clinical profiles 
according to age of AF onset. Better understanding of underlying disease may ultimately 
provide better patient-tailored therapy.
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Supplementary Table 1. Differences between young and older patients, analyzed separately in women and 
men.
Men AF onset < 60yr (n=84) AF onset ≥ 60yr (n=67) P-value
Hypertension 33 (39) 43 (64) 0.002
Diabetes mellitus 7 (8) 14 (21) 0.03
Vascular disease 9 (11) 18 (27) 0.010
Peripheral artery disease - 4 (6) 0.04
Cardiomyopathy 4 (5) - 0.13
Familial AF 20 (24) 6 (9) 0.009
Height (cm) 186±8 180±7 <0.001
Weight (kg) 97±17 89±15 0.007
BMI (kg/m2) 28 ± 4 28 ± 4 0.83
Obesity 25 (30) 19 (28) 0.91
Systolic blood pressure (mmHg) 126±19 131±14 0.09
Physical activity ≥3 times per week 27 (32) 15 (22) 0.04
Physical activity >60 min per activity 16 (19) 6 (9) 0.03
Other ECG abnormalities 8 (10) 5 (8) 0.65
Left atrial parasternal long axis (mm) 40±6 42±6 0.39
Left atrial volume index (ml/m2) 32 (25-40) 36 (26-40) 0.34
Left atrial volume index>34 ml/m2 43 54 0.22
LV mass index (g/m2) 80 (71-94) 83 (71-94) 0.63
LV hypertrophy or remodeling 17 (20) 22 (32) 0.04
Concentric LV remodeling 13 (16) 15 (22) 0.19
Concentric LV hypertrophy 2 (2) 5 (8) 0.14
Eccentric LV hypertrophy 2 (2) 2 (3) 1.00
Diastolic dysfunction 53 82 0.005
LA reservoir function (%) 30±8 27±7 0.06
LA contraction function (%) 12±4 13±5 0.79
LA conduit function (%) 18±7 14±5 0.01
Women  (n=36)  (n=53) P-value
Hypertension 16 (44) 33 (62) 0.10
Diabetes mellitus 2 (6) 4 (8) 1.00
Vascular disease 4(11) 7(13) 1.00
Peripheral artery disease - 1 (2) 1.00
Cardiomyopathy 4 (11) - 0.02
Familial AF 14 (39) 8 (15) 0.006
Height (cm) 172±7 170±7 0.37
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Supplementary Table 1. Differences between young and older patients, analyzed separately in women and 
men. (continued)
Women AF onset < 60yr (n=36) AF onset ≥ 60yr (n=53) P-value
Weight (kg) 87±16 81±13 0.06
BMI (kg/m2) 30± 6 28 ± 5 0.16
Obesity 16 (44) 15 (28) 0.13
Systolic blood pressure (mmHg) 125±19 136±18 0.004
Physical activity ≥3 times per week 10 (28) 9 (17) 0.13
Physical activity >60 min per activity 10 (28) 2 (4) 0.001
Other ECG abnormalities 5 (14) 1 (2) 0.04
Left atrial parasternal long axis (mm) 35±5 39±5 0.007
Left atrial volume index (ml/m2) 31±8 37±12 0.018
Left atrial volume index >34 ml/m2 31 55 0.048
LV mass index (g/m2) 69 (60-80) 78 (71-88) 0.01
LV hypertrophy or remodeling 7 (19) 26 (49) 0.002
Concentric LV remodeling 5 (14) 20 (38) 0.007
Concentric LV hypertrophy - 5 (9) 0.07
Eccentric LV hypertrophy 2 (6) 1 (2) 0.57
Diastolic dysfunction (%) 55 95 <0.001
LA reservoir function (%) 32±9 26±10 0.009
LA contraction function (%) 12±5 12±5 0.91
LA conduit function (%) 20±7 14±7 0.001
Data is expressed as mean±standard deviation(SD), median(IQR) or numbers(%).
Abbreviations: AF=atrial fibrillation; BMI=body mass index; ECG=electrocardiogram; LA=left atrium; LV=left ven-
tricle.
79Clinical profiles in AF
Supplementary Table 2. Sex-age interactions in variables with possible sex-related differences between young 
and older individuals (performed in total group of young and older AF patients (N=240)). 




Peripheral artery disease 1.00






eLog systolic bloodpressure 0.15
Physical activity ≥3 times per week 0.98
Physical activity >60 min per activity 0.16
Other ECG abnormalities 0.14
LA parasternal long axis 0.14
eLog left atrial volume index 0.28
Left atrial volume index >34ml/m2 0.38
LV end-diastolic diameter index 0.41
eLog LV mass index 0.09
Relative wall thickness 0.08
LV hypertrophy or remodeling 0.23
Concentric LV remodeling 0.20
Concentric LV hypertrophy 0.99
Eccentric LV hypertrophy 0.40
Diastolic dysfunction 0.17
LA reservoir(%) 0.22
Model includes age divided in age of AF onset <60 years and age >60 years, sex and interaction term sex * age 
of AF onset (<60 years or >60 years).
Logistic regression was used for binominal dependent variables, linear regression for continuous dependent 
variables.




Risk factors for atrial fibrillation 
progression

